Dasatinib [Sprycel] may increase the risk of pulmonary arterial hypertension (PAH)

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1374, 2011-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dasatinib linked to pulmonary arterial hypertension

By  

Reactions Weekly, Vol. 1, Iss. 1368, 2011-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Dasatinib: Pulmonary arterial hypertension: case report

By  

Reactions Weekly, Vol. 1, Iss. 1432, 2012-01 ,pp. : 20-21

Adis International

Access to resources Recommend Favorite

The long-term use of imatinib may be beneficial for patients with pulmonary arterial hypertension

By  

Inpharma, Vol. 1, Iss. 1555, 2006-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Inhaled treprostinil is an effective, well-tolerated add-on therapy for patients with pulmonary arterial hypertension (PAH) treated with bosentan

By  

Inpharma, Vol. 1, Iss. 1561, 2006-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Sitaxsentan sodium appears to be more cost effective than bosentan in treating patients with pulmonary arterial hypertension (PAH)

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 508, 2006-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite